For years, $50 was the magic number. If a prescription cost more than that out of pocket, patients often left it behind at the pharmacy counter. But in 2025, that number has changed—and so has the urgency of solving the prescription abandonment crisis.
A recent article from GoodRx reveals just how dramatically the landscape has shifted. Their latest data shows abandonment now peaks at out-of-pocket (OOP) costs between $65 and $231. At first glance, it looks like patients have become more tolerant of higher prices.
But the truth is more complex.
What Looks Like Tolerance May Be a Pricing Mirage
There are two reasons we may be seeing abandonment at higher price points:
The walk-away price has increased.
Decades of high-deductible health plans (HDHPs) and rising cost exposure have conditioned patients to expect higher out-of-pocket spending. When a $100 prescription shows up, many still walk away, but they’re less surprised by the price tag.
Fewer prescriptions are priced around $50.
Due to inflation in drug pricing and formulary shifts, many common prescriptions, especially branded or specialty meds, no longer live in the $40–$60 band. That price point is simply disappearing, which means the current abandonment threshold reflects today’s pricing reality more than a shift in patient behavior.
In other words, the walk-away price hasn’t just moved, it’s been pushed.
Patients Falling Through the Cracks
GoodRx’s research and RazorMetrics’ cost containment experience makes one thing clear: abandonment is rising. In 2024 alone, 98 million prescriptions were reversed or abandoned, even as cash pay and copay programs expanded.
While support programs exist, they’re underused. Only 7% of Americans used a manufacturer savings card last year. Patients either don’t know about these options, don’t qualify, or don’t have the time and energy to navigate the process.
Abandonment happens not because patients are unwilling, but because finding savings to make the medication affordable is too difficult to navigate.
Meet the Moment, Upstream
GoodRx addresses abandonment at the pharmacy counter. RazorMetrics solves it further upstream, at the point of prescribing.
We deliver clinically appropriate switch opportunities directly to prescribers through their normal clinic workflow. There are no added clicks, no disruptions to scheduling, and no training required. With a 75% prescriber response rate and a 33% acceptance rate, our approach is built for agility and impact.
When a prescriber approves a switch, the member receives an affordable medication before ever facing a difficult decision at the pharmacy register. The walk-away moment is eliminated before it begins.
We’re Obsessed With Making the Right Choice the Easy One
At RazorMetrics, we’re relentless about solving prescription abandonment at the source. We believe physicians want to make cost-conscious decisions, they just need better visibility. Our platform makes that possible without delays, disruptions, or detours.
We support therapeutic switching, biosimilar exchange, polypharmacy management, and deprescribing — all wrapped into one elite, physician-directed solution that protects plan sponsor budgets and member trust.
The Walk-Away at Any Price is a Problem
While the walk-away price has shifted, abandonment is increasingly more frequent.
That’s why we need coordinated, multi-touch solutions both upstream and downstream. If we want members to stay on therapy and plan sponsors to capture full value from their pharmacy benefits, we need to act earlier, smarter, and faster.
At RazorMetrics, we’re proud to be part of that solution.
